CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
Curis, Inc.
Curis, Inc.
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
M.D. Anderson Cancer Center
Incyte Corporation
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
University of Florida
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
Beijing Biotech
Calibr, a division of Scripps Research
University of Arizona
Masonic Cancer Center, University of Minnesota
Ohio State University Comprehensive Cancer Center
Pfizer
University of Chicago
AbbVie
Thomas Jefferson University
Sellas Life Sciences Group
Cedars-Sinai Medical Center
Baylor College of Medicine
Cancer Research UK
Gamida Cell ltd
National Institutes of Health Clinical Center (CC)
University of Miami
Ascentage Pharma Group Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
M.D. Anderson Cancer Center
City of Hope Medical Center
UNC Lineberger Comprehensive Cancer Center
Prelude Therapeutics
Fred Hutchinson Cancer Center
St. Jude Children's Research Hospital
Brown University
Institute of Hematology and Blood Transfusion, Czech Republic
UNC Lineberger Comprehensive Cancer Center
Affiliated Hospital of Jiangsu University
VA Office of Research and Development
Medical University of Gdansk
Miltenyi Biomedicine GmbH
CellCentric Ltd.
BeOne Medicines
Baylor College of Medicine
University of Salamanca